Stifel Maintains Hold on CRISPR Therapeutics, Lowers Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Hold rating on CRISPR Therapeutics (NASDAQ:CRSP) and lowers the price target from $60 to $59.
August 06, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Benjamin Burnett maintains a Hold rating on CRISPR Therapeutics and lowers the price target from $60 to $59.
The lowered price target from $60 to $59 suggests a slightly more pessimistic outlook on CRISPR Therapeutics' stock performance. This could lead to a minor negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100